Identification of immunologic subtype and prognosis of GBM based on TNFSF14 and immune checkpoint gene expression profiling.

Aging (Albany NY) · 2020 · PMC7202515 · PMID 32310827

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

extremely significantno p-value reported

Considering that TNFSF9 and TNFSF14 were extremely significant poor prognostic factors, we speculated that high expression of TNFSF9 and TNFSF14 would correspond to low TMB, while low TMB would not be suitable for immunotherapy.

also in 7,787 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.